# <sup>1</sup>**Title: STAT4 Phosphorylation of T-helper Cells predicts surgical outcomes in**

# <sup>2</sup>**Refractory Chronic Rhinosinusitis**

- <sup>3</sup>**Running title:** STAT4 predicts success in CRS surgery
- 
- 5 Michael R. Abidin M.D.<sup>1</sup>, Oral Alpan M.D.<sup>2</sup> Matthew Plassmeyer PhD<sup>2</sup>, Lina Kozhaya<sup>3</sup>, Denise
- 6 Loizou RN<sup>2</sup>, Mikail Dogan, M.D<sup>3</sup>, Zachary Upchurch M.D.<sup>1</sup>, Nathan P Manes PhD<sup>4</sup>, Aleksandra
- 7 Nita-Lazar, PhD<sup>4</sup>, Derya Unutmaz, M.D.<sup>3</sup>, Søren Ulrik Sønder PhD<sup>2</sup>
- 
- <sup>1</sup> Metropolitan ENT, 6355 Walker Ln, Alexandria, VA-22310, USA
- 10  $\textdegree$  2 Amerimmune LLC, 8260 Greensboro Dr VA-22102 McLean, USA
- 11 <sup>3</sup>The Jackson Laboratory, Farmington, CT, 06032 USA
- <sup>4</sup> Functional Cellular Networks Section, Laboratory of Immune System Biology, NIAID, NIH,
- 13 USA
- 
- 15 ORCID
- 16 Michael R. Abidin M.D.<sup>1</sup> 0000-0001-5679-6667
- 17 Oral Alpan M.D.<sup>2</sup> 0000-0001-7467-8541
- 18 Matthew Plassmeyer PhD<sup>2</sup> 0000-0001-8068-2125
- 19 Lina Kozhaya<sup>3</sup> 0000-0002-1559-2278
- 20 Denise Loizou  $RN^2$
- 21 Zachary Upchurch M.D 0009-0001-1357-5765
- 22 Nathan P Manes PhD<sup>4</sup> 0000-0001-6701-3314
- 23 Aleksandra Nita-Lazar Ph $D^4$  0000-0002-8523-605X

- 24 Mikail Dogan M.D<sup>3</sup> 0000-0001-8725-9151
- 25 Derya Unutmaz, M.D.<sup>3</sup> 0000-0001-8898-6633
- 26 Søren Ulrik Sønder PhD<sup>2</sup> 0000-0002-4697-8421
- <sup>27</sup>Corresponding Author: Søren Ulrik Sønder,
- <sup>28</sup>ssonder@amerimmune.com
- 29<sup>571-308-1900</sup>
- 
- 31 Previous publication: This paper is uploaded to Medrxiv
- 32 Keywords: Chronic Refractory Sinusitis, CRS, flow cytometry, T-cells, CD4, STAT4,
- 33 phosphorylation, Cohort study
- <sup>34</sup>**Conflict of interest:** The Author(s) declare(s) that there is no conflict of interest.

#### <sup>35</sup>**Contributions:**

- <sup>36</sup>Michael R. Abidin: Design, Conduct, Analysis
- 37 Oral Alpan: Design, Conduct, Analysis
- 38 Matthew Plassmeyer: Conduct, Analysis
- 39 Lina Kozhaya: Conduct, Analysis
- 40 Denise Loizou: Conduct
- <sup>41</sup>Zachary Upchurch: Conduct
- 42 Nathan P Manes: Conduct, Analysis
- 43 Aleksandra Nita-Lazar: Design
- 44 Mikail Dogan: Conduct, Analysis
- 45 Derya Unutmaz: Design, Analysis

<sup>46</sup>Søren Ulrik Sønder: Design, Conduct, Analysis

- 48 Funding source: This study was supported by Amerimmune. This study was supported in part by
- 49 the Intramural Research Program of NIAID, NIH and internal funds to D.U. at Jackson
- 50 Laboratory.

#### <sup>51</sup>**Abstract:**

52 Objective: Chronic rhinosinusitis (CRS) impacts an estimated 5% to 15% of people worldwide,

53 incurring significant economic healthcare burden. There is a urgent need for the discovery of

54 predictive biomarkers to improve treatment strategies and outcomes for CRS patients.

<sup>55</sup>Study design: Cohort study of CRS patients and healthy controls using blood samples.

56 Setting: Out-patient clinics.

57 Methods: Whole blood samples were collected for flow cytometric analysis. Mechanistic studies 58 involved the transfection of human primary T cells and Jurkat cells.

59 Results: Our analysis began with a 63-69 year-old female patient diagnosed with refractory

<sup>60</sup>CRS,. Despite undergoing multiple surgeries, she continually faced sinus infections. Whole

61 exome sequencing pinpointed a heterozygous IL-12Rb1 mutation situated in the linker region

62 adjacent to the cytokine binding domain. When subjected to  $IL-12$  stimulation, the patient's CD4

<sup>63</sup>T-cells exhibited diminished STAT4 phosphorylation. However, computer modeling or T-cell

64 lines harboring the same IL-12 receptor mutation did not corroborate the hypothesis that IL-

<sup>65</sup>12Rb could be responsible for the reduced phosphorylation of STAT4 by IL-12 stimulation.

<sup>66</sup>Upon expanding our investigation to a broader CRS patient group using the pSTAT4 assay, we

67 discerned a subset of refractory CRS patients with abnormally low STAT4 phosphorylation.

<sup>68</sup>The deficiency showed improvement both in-vitro and in-vivo after exposure to *Latilactobacillus* 

<sup>69</sup>*sakei* (aka *Lactobacillus sakei*), an effect at least partially dependent on IL-12.

<sup>70</sup>Conclusion: In refractory CRS patients, an identified STAT4 defect correlates with poor clinical

<sup>71</sup>outcomes after sinus surgery, which can be therapeutically targeted by *Latilactobacillus sakei* 

72 treatment. Prospective double-blind placebo-controlled trials are needed to validate our findings.

# **Introduction**



89 Disruption of this axis could compromise the ability of the immune system to handle microbial challenges, leading to persistent infections and prolonged inflammation. Indeed, a balanced IL-91 12/IFN-γ response is essential to clear pathogens, maintain mucosal homeostasis, and prevent 92 tissue damage in the sinuses [1]. Furthermore, recurrent infections, which denote a failure of the immune system to provide lasting protection after initial exposure to a pathogen, may also be 94 linked to perturbations in the IL-12/IFN- $\gamma$  pathway. An impaired or inadequate IL-12-driven IFN-γ response may not only decrease resistance to primary infections but might also reduce 96 immune memory, rendering individuals more susceptible to recurrent bouts of infections despite

97 adequate surgical intervention  $[1,7-13]$ . Although T-cell defects are the most common immune 98 disorder in chronic rhinosinusitis (CRS), clinical workup towards its identification is rarely 99 performed.

100

101 Various dietary supplements have been demonstrated to enhance Th1 responses. Among them 102 included are various lactobacillus probiotic supplements. Although the role of lactobacillus 103 containing supplements, taken orally or topically, is unproven in patients with CRS, small sized 104 studies and anecdotal reports did find correlations with clinical outcomes in the surgical healing 105 process [14–20]. Data from preliminary studies have shown mixed results in patients receiving 106 probiotics containing lactobacilli species. Lactobacilli have the potential of inducing IL-12 from 107 macrophages  $[21-23]$ .

109 Our investigation began with a case of refractory chronic rhinosinusitis (RCRS) associated with 110 a heterozygous IL-12 receptor mutation. Despite observing decreased STAT4 phosphorylation in 111 response to IL-12 stimulation in both the patient and her children, the mutation itself was not 112 proven to be the cause. Further research revealed this decreased phosphorylation to be a common <sup>113</sup>characteristic in a broader RCRS patient cohort. Insights into the IL-12/IFN-γ signaling 114 pathway's role in CRS may unveil new therapeutic targets to enhance immunity, alleviate 115 chronic inflammation, and decrease recurrent infections.

116

#### <sup>117</sup>**Materials and Methods:**

<sup>118</sup>**Patients and ethical statement.** 





### <sup>160</sup>**Data analysis and modelling.**

161 Data analysis of flow cytometry data was performed using FCS Express software (De Novo

162 software, Glendale, CA). All data comparisons were analyzed as paired, two tailed, two-sample

163 unequal variance using Student's t-test to determine significance. A p-value less than 0.05 was

164 considered significant, \*  $p<0.05$ , \*\*  $p<0.01$ .

#### 165

- 166 Protein structure modeling was performed using AlphaFold [28]. The resulting models were
- 167 aligned and visualized using Chimera<sup>[29]</sup>.
- 168

#### <sup>169</sup>**Plasmid constructs**

- 170 Human codon-optimized wild-type IL-12Rb1 and IL-12Rb2 protein sequences were synthesized
- 171 by MolecularCloud (HG11674-UT and HG10145-UT, respectively) and then cloned into
- 172 lentiviral plasmid constructs with RFP and GFP reporters, respectively. The overlap extension
- 173 PCR method was used to generate the mutant IL12Rb1 Q238E protein sequence and clone it into
- 174 the lentivector. IL-12Rb1 Q238E sequence was then confirmed using sequencing by Eton Bio.
- 175 Primer sequences are available upon request.
- 

#### <sup>177</sup>**Lentivirus production**

- <sup>178</sup>The lentiviruses pseudotyped with vesicular stomatitis virus G protein envelope were generated
- 179 with HEK293T cells using Lipofectamine 3000 (Invitrogen) according to the manufacturer's

180 protocol as previously described [30].

#### <sup>182</sup>**Engineering primary human T cells and Jurkat cells**

183 Healthy adult blood was obtained from AllCells. Primary CD4 T cells were isolated, activated,

184 transduced to overexpress IL12Rb1 wild-type or mutant, and proliferated as previously described

- <sup>185</sup>[31]. Total PBMC were activated with antiCD3/anti-CD28 dynabeads (Invitrogen) and expanded
- 186 in IL-2 (10ng/ml) containing media. To generate IL12Rb1 wild-type or mutant and IL12Rb2
- 187 overexpressing Jurkat cells, wild-type Jurkats were transduced with the IL-12Rb2 lentiviruses,



### **Statistical Analyses and Reproducibility**

206 All statistical analyses were performed, and graphs were prepared using GraphPad Prism V9 207 software. Each experiment was performed at least three times and non-parametric t-tests were 208 used for statistical significance analyses.

# **Results**

### <sup>211</sup>**Identification of a Th1 defect in a family of patients with RCRS.**

212 The patient is a 63-69 year-old Caucasian female with a long-standing history of chronic 213 pansinusitis without polyps, and osteomyelitis of the right maxillary sinus wall. Sinus cultures <sup>214</sup>grew methicillin resistant S. aureus and Klebsiella species on multiple occasions. Patients 215 underwent multiple sinus surgeries and procedures involving ethmoid, maxillary and frontal 216 sinuses. Sinus surgical pathology results show predominantly neutrophilic infiltrates (Figure 1A). 217 The patient's immune evaluation showed slight hypogammaglobulinemia (400-500 mg/dL) 218 range) on multiple occasions along with poor responses to S. pneumoniae serotypes  $(3/14$  of the 219 serotypes with protective levels above 1.3 mcg/ml despite multiple boosters with Pneumovax23). 220 Serum IgM, IgA and IgE levels were within normal limits. The patient's B cells expressed 221 normal CD27, IgG, IgA, IgM and IgD, arguing against a primary antibody deficiency disorder. <sup>222</sup>T-cells, including T-cell subsets and NK cells were normal for absolute numbers and 223 percentages. Given the poor response to antibiotic therapies, and persistently borderline low IgG, 224 the patient was started on  $I_{\mathcal{B}}$  replacement therapy which resulted in partial clinical 225 improvement of the sinus disease. 226

<sup>227</sup>Since the patient's clinical presentation was not fully explained by the low serum IgG and only a 228 partial clinical response to the IgG replacement therapy, whole exome sequencing was 229 performed, which revealed a heterozygous mutation in the  $IL12RB1$  gene, 712 C>G resulting in 230 the p.Gln238Glu variant. The variance was confirmed by Sanger sequencing in the patient as 231 well as in four of her five children (Figure 1B+1C). The p.Gln238Glu variant is classified as a 232 variant of uncertain significance (VUS) in ClinVar[32]. The structure modeling of the molecular <sup>233</sup>defect maps it to the linker region to the cytokine binding domain (Supplemental figure 1). The



247 To identify the Th1 defect, we measured the phosphorylation of STAT4 in response to IL-12 248 stimulation in  $CD3^+/CD4^+/CD45RO^+$  cells at various time points between 0 and 5 hours. The 249 result for the patient is an average of three samples each collected a month apart. They were 250 compared to a group of age matched healthy controls  $(n=5)$  and patients with various well 251 defined immune deficiencies requiring antibody replacement therapy  $(n=5)$ . Healthy controls 252 showed an increase in percentage of p-STAT4 positive T-helper memory cells after 30 minutes 253 of stimulation with IL-12 which peaked after  $60-120$  minutes followed by a slow decrease after 254 180 minutes. The patient's p-STAT4 response was significantly blunted at all time points. <sup>255</sup>(Figure 4A and 4B).

256

<sup>257</sup>We subsequently tested four of the patient's adult children. The IL-12 induced STAT4 258 phosphorylation showed that the three siblings with the mutation showed a lower peak in STAT4 259 phosphorylation after 60 minutes compared to the sibling without the mutation (Figure 4C). One 260 of the three siblings with the mutation had a history of recurrent sinusitis and pneumonia. 261 <sup>262</sup>**Transfection Experiments to show the impact of Q2883 mutation on primary T cells.**  263 The modeling of the IL12 receptor did not show any difference in the folding of the receptor 264 between the wild type and the p.Gln238Glu variant (Supplemental Figure 1). To determine 265 whether the mutated IL12 receptor is the cause of the defective STAT4 phosphorylation, we first 266 engineered primary  $CD4^+$  T cells to overexpress the WT or the mutated IL-12Rb1 (Supplemental 267 Figure 2). We saw no difference in the phosphorylation of STAT4 on IL12 stimulation in these 268 primary  $CD4^+$  T cells when compared those engineered to express wild-type or mutant IL12Rb1. <sup>269</sup>(Supplemental Figure 3). A significant challenge posed by this system is the mosaicism of the 270 cells harboring the mutant receptors, as they also express normal IL12b1 receptors constitutively. 271 Consequently, IL12 may exhibit a preferential activation of the normal receptor, complicating 272 the functional analysis of the mutant variant. To address this issue, we utilized Jurkat cells, 273 which are deficient in IL12b1. Jurkat cells also express high levels of STAT4 constitutively <sup>274</sup>(Figure 5). Thus, we genetically expressed either the wild-type (WT) or the mutant variant of 275 this receptor in Jurkat cells along with the IL-12Rb2, which is required to form heterodimer with 276 IL-12Rb1 for the signaling via IL-12 (Supplemental Figure 4). In these genetically engineered 277 Jurkat cells, upon stimulation with IL-12 we could detect phosphorylation of STAT4, but not 278 wild type Jurkat line, suggesting efficient reconstitution of the receptor complex for this 279 signaling pathway. Overexpression of IL12Rb1 and IL12Rb2 genes also led to high level

![](_page_13_Picture_122.jpeg)

299

# <sup>300</sup>**Validation of the pSTAT4 assay**

301 In the context of CRS, dysbiosis in the upper airway microbiome can influence IL12 signaling. 302 For example, mucin-fermenting bacteria in CRS may degrade and ferment mucins, altering the

303 airway environment and promoting inflammation that could disrupt  $[L12$  signaling [33].

- 304 Additionally, elevated short chain fatty acid levels in CRS mucus may also impact this pathway
- <sup>305</sup>[34]. This suggests that apart from genetic factors, extrinsic factors, such as microbial
- 306 imbalances could contribute to IL12 signaling defects in CRS.

<sup>307</sup>To test this hypothesis, we next sought to test a larger cohort of patients with RCRS, to see if the

308 variability we see in the pSTAT4 levels in the clones is reflected between patients. The

309 phosphorylation of STAT4 after IL-12 stimulation allows for a functional readout of the

310 signaling regardless of the location of the genetic variations in the IL-12/IFNγ axis or molecules

311 that influence it, which can vary between patients. To do this, we first validated the assay so that

312 the results are consistent and that it can be included in the clinical workup of patients with CRS.

313 The previously published pSTAT4 assay, used to study IL-12 receptor mutations, relied on the

314 hypothetical approach of maximizing IL-12 receptor expression by inducing blastogenesis using

315 PHA, a process that typically takes 5-7 days. The blasts are then subsequently stimulated with

 $316$  IL-12 [35–37]. This approach can be employed in a research setting to demonstrate that IL-12

317 receptor mutations can disrupt IL-12 signaling. However, it is not well-suited for routine clinical

318 testing due to the challenges associated with validating a multistep process that involves

319 numerous variables in blastogenesis. Additionally, blasts may not accurately reflect a

320 physiological response in vivo, as the majority of circulating cells are not in a continuous

321 activated state. Furthermore, our findings indicate that the expression of T cell surface IL-12

322 receptors remains unchanged between resting T cells and blasts. (Supplemental Figure 5). The

323 pSTAT4 assay performed on resting primary T cells and validated under CAP/CLIA utilizes

324 whole blood within 24 hours [26]. The assay measures STAT4 phosphorylation at multiple time

 $325$  points, extending up to 2 hours, and can be finalized within 5 hours. It exhibits high

- 326 reproducibility and is accompanied by reference ranges, enabling us to assess a patient's
- 327 condition without the need to include a group of healthy controls.
- 

#### <sup>329</sup>**pSTAT4 to screen CRS for prolonged surgical recovery.**

330 In addition to the results from our Jurkat clones showing variability in STAT4 phosphorylation, 331 the published reports on T cell defects in up to 56% of RCRS patients supported our approach to 332 screen a larger cohort of RCRS patients [38]. To assess the clinical relevance of our finding in 333 the larger RCRS population, we used the IL-12 induced pSTAT4 as a screening assay in  $147$ <sup>334</sup>RCRS patients requiring surgery (Figure 8 and Supplemental Figure 6). These RCRS patients 335 presented with infections of Klebsiella, Staphylococcus, Serratia and Burkholderia species 336 isolated from sinus cultures, and had history of multiple sinus procedures, no polyps. These 337 patient's nasal mucosa showed areas of inflammation, often with one side or another showing <sup>338</sup>much worse disease, rather than widespread inflammation. Chronic inflammatory infiltrates were 339 common to all RCRS patients' tissue specimens, performed as a part of their post-surgical 340 specimen processing. Bad surgical outcome was defined as requiring more than two courses of 341 antibiotic therapy within the first 6 months after surgery. Low STAT4 phosphorylation 342 correlated with prolonged surgical recovery of lengthy healing process as well as persistence of 343 the sinus infections. None of the individuals in the control group or the patients with a good 344 surgical outcome had a pSTAT4 value below 5% whereas most of the patients with poor surgical 345 outcome had a value below 5%. To test if a soluble factor (i.e. anti-cytokine antibody) was 346 responsible for low STAT4 phosphorylation, we performed the experiments on health subjects <sup>347</sup>CD4 T cells using RCRS patient serum. Serum of RCRS patients with low pSTAT4 did not

348 result in healthy patients' cells down-regulating STAT4 phosphorylation in response to IL-12 349 stimulation (Supplemental figure 7).

#### <sup>351</sup>**Effect of Lactobacilli on STAT4 phosphorylation in-vitro and in vivo**

<sup>352</sup>In our follow-up experiments, we explored the potential impact of lactobacilli on pSTAT4 353 phosphorylation. This investigation was prompted by data suggesting that specific lactobacilli 354 strains can trigger IL-12 production in macrophages and by anecdotal observations within our <sup>355</sup>group regarding the potential clinical advantages of probiotics in chronic sinus disease. Our 356 results demonstrated that when PBMCs were exposed to a lactobacilli solution containing L. 357 acidophilus for 18 hours, STAT4 phosphorylation was induced, even in the absence of 358 exogenous IL-12 supplementation. Intriguingly, when the lactobacilli solution was introduced to 359 PBMCs of patients exhibiting low STAT4 phosphorylation in their CD4 T-cells, there was a 360 notable enhancement in STAT4 phosphorylation. This effect was partially inhibited by 361 neutralizing anti-IL12 antibodies (Figure 9). This suggests that the probiotic's effect can be 362 attributed to IL12 production but contributions from an IL-12 independent pathway could not be 363 ruled out. The phosphorylation of STAT4 by lactobacilli, as well as its inhibition of IL-12, 364 exhibits specificity to both the bacterial strain and the host (Supplemental Figure 8). 365

<sup>366</sup>In light of these findings, we conducted a retrospective review of medical records for 25 CRS 367 patients who were administered *Latilactobacillus sakei*, a strain reported for its ability to induce 368 exceptionally high IL-12 levels  $[39]$ . We gauged the patients' response to the probiotic by 369 correlating the number of postoperative office visits and change in pSTAT4 levels pre-and post-370 probiotic use in a 1-year period. The results present pSTAT4 levels as a percentage change, and

371 the outpatient data reflect the difference in visit frequency. Our analysis underscored a positive

372 correlation between the frequency of patients' post-surgical visits and the pSTAT4

 $373$  phosphorylation in their CD4 T cells (Figure 10).

374

### <sup>375</sup>**Discussion**

376 CRS remains a nuanced pathology, both in its presentation and underlying etiologies. In this

377 study, we started out with exploring a VUS in the IL-12 receptor beta 1 of an RCRS patient.

378 Despite the patient's receptor expressing normally on peripheral blood T-helper cells, our

 $379$  discoveries highlighted a compromised IL-12 signaling. Even though there is a correlation in the

380 patient's family between individuals with the mutation and low pSTAT4 response we were

381 unable to show an effect of the mutation in computational structural simulation models or by *in* 

<sup>382</sup>*vitro* transfection experiments.

384 Broadening our scope, we undertook a validated pSTAT4 assay across an expansive cohort of 385 RCRS patients. The outcome was illuminating; diminished STAT4 phosphorylation in CD4 T-386 cells heralded poor post-surgical recoveries. While this finding seemed to be a validation of prior 387 research emphasizing T-cells' pivotal roles in RCRS, it also accentuated a conspicuous gap in 388 clinical practice: the lack of routine cellular immunity assessments of these patients, despite their 389 potential diagnostic importance. The common practice of immune evaluation of CRS involves <sup>390</sup>measuring serum quantitative antibody levels, which, more often than not, provide inconclusive  $391$  results [25,40,41]. As this research underscores specific defects in T cell function and offers a 392 clinically validated diagnostic tool, we anticipate a paradigm shift towards more tailored 393 therapeutic approaches for RCRS. However, unveiling the exact mechanics behind impaired IL-

<sup>394</sup>12-mediated STAT4 phosphorylation remains to be determined, the deciphering of which could 395 usher in therapeutic breakthroughs.

<sup>397</sup>Another riveting aspect of our study revolves around the interplay between Lactobacillus species 398 and the immune system. With their presence predominantly in the human gut, Lactobacillus 399 species' interactions with macrophages can influence cytokine profiles, including IL-12 [42]. We <sup>400</sup>confirmed this in our *in vitro* analysis using neutralizing IL-12 antibodies which reduced the <sup>401</sup>effect of *L. acidophilus*. Furthermore, the *L. acidophilus* was able to induce STAT4  $402$  phosphorylation in the absence of any exogenous IL-12. But not all Lactobacilli are created 403 equal. Potentially, strain-specific variability can exist in their potency to modulate IL-12, 404 potentially attributed to differences in their cell walls [43]. This study further delves into this <sup>405</sup>variability, reinforcing the importance of strategic Lactobacillus selection in potential therapeutic <sup>406</sup>endeavors. The precise mechanism of Lactobacillus stimulation of T cells is not entirely known 407 and our data shows both IL-12 independent as well as dependent phosphorylation of STAT4. <sup>408</sup>The STAT4 phosphorylation we observe in Figure 9A is lower than what we see when saturating 409 the blood sample with IL-12, but it is likely to be adequate, *in vivo*, to activate and poise the Th-1 410 cells in patients with low pSTAT4 response and lead to improved clinical outcomes in 411 postsurgical RCRS patients.

412

Our Lactobacillus data provide important insights into the inconsistent findings in the literature concerning the clinical effects of Lactobacillus on Chronic Rhinosinusitis (CRS) outcomes. The 415 data highlight two key factors: Firstly, the specific strains of probiotics and individual host characteristics significantly influence STAT4 phosphorylation. This effect's strength and its IL-

417 12 dependence vary, as evidenced by the inhibition assays presented in Figure 5 and <sup>418</sup>Supplementary Figure 8. Future research should identify the probiotic structural components <sup>419</sup>responsible for these effects. Secondly, the choice of clinical endpoints is crucial. Given that 420 STAT4 phosphorylation is pivotal in regulating Th1 cell responses, our research prioritized post-421 surgical wound healing rather than improvements in clinical symptoms or reductions in sinus 422 infection rates. [44–46]. The process of wound healing begins with an immediate inflammatory 423 response, seeing an influx of various cellular actors. Th1 cells, through their influence on <sup>424</sup>macrophages and fibroblasts and their production of IFN-γ, impact collagen synthesis, the 425 bedrock of tissue repair [47]. However, maintaining a balance in Th1 activity is paramount. An 426 overwhelming or inadequate Th1 response can either prolong inflammation or inadequately 427 support the initial healing phases, respectively. As such, understanding Th1 activity, primarily 428 via STAT4 phosphorylation, provides invaluable insights into predicting and optimizing surgical 429 outcomes. Furthermore, the microbiota can induce an adaptive immune response that can couple 430 antimicrobial function with tissue repair and wound healing [48]. It has been shown that non-431 classical MHC class I molecules, an evolutionarily ancient arm of the immune system, can 432 promote immunity to the microbiota, such as Lactobacillus, and subsequently affect cytokine 433 signaling, including IL-12 [49]. To enhance our understanding of Recurrent Chronic 434 Rhinosinusitis (RCRS), it is crucial to conduct prospective studies focusing on the IL-12 435 pathway. Investigating its specific functions could provide insights into its dual role in infection 436 control and inflammation regulation.

![](_page_20_Picture_124.jpeg)

# <sup>453</sup>**Conclusion**

454 As our grasp of RCRS and its complex underlying mechanisms grows, evaluating T-cell defects

455 using the STAT4 phosphorylation assay described in this study emerges as a particularly

456 promising avenue. These innovative diagnostic and therapeutic strategies that evolve from them,

457 have the potential to transform our management of CRS. When utilized with precision, they offer

458 a path toward alleviating the substantial strain that CRS places on healthcare systems.

459

## <sup>460</sup>**References**

- 461 [1] Rosenzweig SD, Holland SM. Defects in the interferon-gamma and interleukin-12 pathways.<br>462 Immunol Rev 2005;203:38–47. https://doi.org/10.1111/j.0105-2896.2005.00227.x.
- 462 Immunol Rev 2005;203:38–47. https://doi.org/10.1111/j.0105-2896.2005.00227.x.<br>463 [2] Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification <sup>463</sup>[2] Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification 464 of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human<br>465 lymphocytes. J Exp Med 1989;170:827–45. https://doi.org/10.1084/jem.170.3.827.
- 1465 lymphocytes. J Exp Med 1989;170:827–45. https://doi.org/10.1084/jem.170.3.827.<br>466 [3] Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in i 466 [3] Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009;8:40–52. 467 inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009;8:40–52.<br>468 https://doi.org/10.2174/187152809787582507.
- 468 https://doi.org/10.2174/187152809787582507.<br>469 [4] Malmgaard L. Induction and regulation of IFNs 469 [4] Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res<br>470 2004;24:439–54. https://doi.org/10.1089/1079990041689665. 470 2004;24:439–54. https://doi.org/10.1089/1079990041689665.<br>471 [5] Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, M
- 471 [5] Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, Montagna C, et al. STAT4 serine<br>472 **https://el. approximates/state/state/state/state/state/state/state/state/state/state/state/state/state/state/state/state/** phosphorylation is critical for IL-12-induced IFN-γ production but not for cell proliferation. Proc<br>473 Matl Acad Sci USA 2002;99:12281–6. https://doi.org/10.1073/pnas.182618999.
- 473 Natl Acad Sci USA 2002;99:12281–6. https://doi.org/10.1073/pnas.182618999.<br>474 [6] Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu C-Y, et al. A function 474 [6] Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu C-Y, et al. A functional interleukin 12 receptor complex is composed of two β-type cytokine receptor subunits. Proc Natl Acad Sci USA 475 receptor complex is composed of two β-type cytokine receptor subunits. Proc Natl Acad Sci USA<br>476 1996;93:14002–7. https://doi.org/10.1073/pnas.93.24.14002.
- 476 1996;93:14002–7. https://doi.org/10.1073/pnas.93.24.14002.<br>477 [7] De Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boi 477 [7] De Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al.<br>478 **Exercise Revisiting Human IL-12Rβ1 Deficiency:** A Survey of 141 Patients From 30 Countries. Medici 478 Revisiting Human IL-12Rβ1 Deficiency: A Survey of 141 Patients From 30 Countries. Medicine<br>479 2010;89:381–402. https://doi.org/10.1097/MD.0b013e3181fdd832.
- 479 2010;89:381–402. https://doi.org/10.1097/MD.0b013e3181fdd832.<br>480 [8] Van De Vosse E, Haverkamp MH, Ramirez-Alejo N, Martinez-Gal. 480 [8] Van De Vosse E, Haverkamp MH, Ramirez-Alejo N, Martinez-Gallo M, Blancas-Galicia L, Metin A, et al. IL-12R $\beta$ 1 Deficiency: Mutation Update and Description of the *IL12RB1* Variation <sup>481</sup>A, et al. IL-12Rβ1 Deficiency: Mutation Update and Description of the *IL12RB1* Variation
- 482 Database. Human Mutation 2013;34:1329–39. https://doi.org/10.1002/humu.22380.<br>483 [9] Fieschi C, Dupuis S, Catherinot E, Feinberg J, Bustamante J, Breiman A, et al. Low 483 [9] Fieschi C, Dupuis S, Catherinot E, Feinberg J, Bustamante J, Breiman A, et al. Low Penetrance,<br>484 Broad Resistance, and Favorable Outcome of Interleukin 12 Receptor  $\beta$ 1 Deficiency. The Journa 484 Broad Resistance, and Favorable Outcome of Interleukin 12 Receptor β1 Deficiency. The Journal of Experimental Medicine 2003;197:527–35. https://doi.org/10.1084/jem.20021769.
- 485 Experimental Medicine 2003;197:527–35. https://doi.org/10.1084/jem.20021769.<br>486 [10] Rosain J, Oleaga-Quintas C, Deswarte C, Verdin H, Marot S, Syridou G, et al. A V 486 [10] Rosain J, Oleaga-Quintas C, Deswarte C, Verdin H, Marot S, Syridou G, et al. A Variety of Alu-487 Mediated Copy Number Variations Can Underlie IL-12Rβ1 Deficiency. J Clin Immunol<br>488 2018:38:617–27. https://doi.org/10.1007/s10875-018-0527-6.
- 488 2018;38:617–27. https://doi.org/10.1007/s10875-018-0527-6.<br>489 [11] Bustamante J, Boisson-Dupuis S, Abel L, Casanova J-L. Meno 489 [11] Bustamante J, Boisson-Dupuis S, Abel L, Casanova J-L. Mendelian susceptibility to mycobacterial disease: Genetic, immunological, and clinical features of inborn errors of IFN- $\gamma$  immunity. Seminars 490 disease: Genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Seminars in Immunology 2014;26:454–70. https://doi.org/10.1016/j.smim.2014.09.008.
- 491 in Immunology 2014;26:454–70. https://doi.org/10.1016/j.smim.2014.09.008.<br>492 [12] Cleary AM, Tu W, Enright A, Giffon T, Dewaal-Malefyt R, Gutierrez K, et al. <sup>492</sup>[12] Cleary AM, Tu W, Enright A, Giffon T, Dewaal-Malefyt R, Gutierrez K, et al. Impaired Accumulation and Function of Memory CD4 T Cells in Human IL-12 Receptor β1 Deficiency. The<br>494 Journal of Immunology 2003;170:597–603. https://doi.org/10.4049/jimmunol.170.1.597. 494 Journal of Immunology 2003;170:597–603. https://doi.org/10.4049/jimmunol.170.1.597.<br>495 [13] Jacobson NG, Szabo SJ, Güler ML, Gorham JD, Murphy KM. Regulation of interleukin-
- 495 [13] Jacobson NG, Szabo SJ, Güler ML, Gorham JD, Murphy KM. Regulation of interleukin-12<br>496 signalling during T helper phenotype development. Adv Exp Med Biol 1996;409:61–73. 496 signalling during T helper phenotype development. Adv Exp Med Biol 1996;409:61–73.<br>497 https://doi.org/10.1007/978-1-4615-5855-2 9. 497 https://doi.org/10.1007/978-1-4615-5855-2\_9.<br>498 [14] Smith A, Buchinsky FJ, Post JC. Eradicating c
- 498 [14] Smith A, Buchinsky FJ, Post JC. Eradicating chronic ear, nose, and throat infections: a systematically conducted literature review of advances in biofilm treatment. Otolarynge 499 systematically conducted literature review of advances in biofilm treatment. Otolaryngol Head Neck<br>500 Surg 2011;144:338–47. https://doi.org/10.1177/0194599810391620. 500 Surg 2011;144:338–47. https://doi.org/10.1177/0194599810391620.<br>501 [15] Lee VS. Topical Irrigations for Chronic Rhinosinusitis. Immunol Alle
- 501 [15] Lee VS. Topical Irrigations for Chronic Rhinosinusitis. Immunol Allergy Clin North Am 2020;40:317–28. https://doi.org/10.1016/j.iac.2019.12.014. 502 2020;40:317–28. https://doi.org/10.1016/j.iac.2019.12.014.<br>503 [16] Czibulka A. Probiotics for Otolaryngologic Disorders. Otola
- 503 [16] Czibulka A. Probiotics for Otolaryngologic Disorders. Otolaryngol Clin North Am 2022;55:939–46.<br>504 https://doi.org/10.1016/i.otc.2022.06.003. 504 https://doi.org/10.1016/j.otc.2022.06.003.<br>505 [17] Psaltis AJ, Mackenzie BW, Cope EK, Ran
- 505 [17] Psaltis AJ, Mackenzie BW, Cope EK, Ramakrishnan VR. Unraveling the role of the microbiome in chronic rhinosinusitis. J Allergy Clin Immunol 2022;149:1513–21. 506 chronic rhinosinusitis. J Allergy Clin Immunol 2022;149:1513–21.<br>507 https://doi.org/10.1016/j.jaci.2022.02.022.
- 507 https://doi.org/10.1016/j.jaci.2022.02.022.<br>508 [18] Bourdillon AT, Edwards HA, Review of p. 508 [18] Bourdillon AT, Edwards HA. Review of probiotic use in otolaryngology. Am J Otolaryngol<br>509 2021;42:102883. https://doi.org/10.1016/j.amjoto.2020.102883.
- 509 2021;42:102883. https://doi.org/10.1016/j.amjoto.2020.102883.<br>510 [19] Cervin AU. The Potential for Topical Probiotic Treatment of Ch 510 [19] Cervin AU. The Potential for Topical Probiotic Treatment of Chronic Rhinosinusitis, a Personal<br>511 Perspective. Front Cell Infect Microbiol 2017;7:530. https://doi.org/10.3389/fcimb.2017.00530. <sup>511</sup>Perspective. Front Cell Infect Microbiol 2017;7:530. https://doi.org/10.3389/fcimb.2017.00530.

- 512 [20] Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal<br>513 pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 513 pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev<br>514 2010:CD001176. https://doi.org/10.1002/14651858.CD001176.pub2.
- 514 2010:CD001176. https://doi.org/10.1002/14651858.CD001176.pub2.<br>515 [21] Yazdi MH, Soltan Dallal MM, Hassan ZM, Holakuyee M, Agha Amii 515 [21] Yazdi MH, Soltan Dallal MM, Hassan ZM, Holakuyee M, Agha Amiri S, Abolhassani M, et al.<br>516 **Calcular** Oral administration of Lactobacillus acidophilus induces IL-12 production in spleen cell culture 516 Oral administration of Lactobacillus acidophilus induces IL-12 production in spleen cell culture of BALB/c mice bearing transplanted breast tumour. Br J Nutr 2010;104:227–32. 517 BALB/c mice bearing transplanted breast tumour. Br J Nutr 2010;104:227–32.<br>518 https://doi.org/10.1017/S0007114510000516.
- 518 https://doi.org/10.1017/S0007114510000516.<br>519 [22] Shida K, Kiyoshima-Shibata J, Kaji R, Nagaol 519 [22] Shida K, Kiyoshima-Shibata J, Kaji R, Nagaoka M, Nanno M. Peptidoglycan from lactobacilli<br>520 inhibits interleukin-12 production by macrophages induced by Lactobacillus casei through Toll 520 inhibits interleukin-12 production by macrophages induced by Lactobacillus casei through Toll-like<br>521 eeeptor 2-dependent and independent mechanisms. Immunology 2009;128:e858-869. 521 receptor 2-dependent and independent mechanisms. Immunology 2009;128:e858-869.<br>522 https://doi.org/10.1111/j.1365-2567.2009.03095.x.
- 522 https://doi.org/10.1111/j.1365-2567.2009.03095.x.<br>523 [23] Shida K, Kiyoshima-Shibata J, Nagaoka M, Watan 523 [23] Shida K, Kiyoshima-Shibata J, Nagaoka M, Watanabe K, Nanno M. Induction of interleukin-12 by<br>524 Lactobacillus strains having a rigid cell wall resistant to intracellular digestion. J Dairy Sci 524 Lactobacillus strains having a rigid cell wall resistant to intracellular digestion. J Dairy Sci<br>525 2006;89:3306–17. https://doi.org/10.3168/jds.S0022-0302(06)72367-0. 525 2006;89:3306–17. https://doi.org/10.3168/jds.S0022-0302(06)72367-0.<br>526 [24] Desrosiers M. Refractory chronic rhinosinusitis: pathophysiology and m
- 526 [24] Desrosiers M. Refractory chronic rhinosinusitis: pathophysiology and management of chronic rhinosinusitis persisting after endoscopic sinus surgery. Curr Allergy Asthma Rep 2004;4:200-527 rhinosinusitis persisting after endoscopic sinus surgery. Curr Allergy Asthma Rep 2004;4:200–7.<br>528 https://doi.org/10.1007/s11882-004-0027-z. 528 https://doi.org/10.1007/s11882-004-0027-z.<br>529 [25] Rosenfeld RM, Piccirillo JF, Chandrasekhar
- 529 [25] Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M, et al.<br>530 Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 2015;152:S1 530 Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 2015;152:S1–39.<br>531 https://doi.org/10.1177/0194599815572097. 531 https://doi.org/10.1177/0194599815572097.<br>532 [26] PSTAT Validation — Amerimmune n.d. http:
- 532 [26] PSTAT Validation Amerimmune n.d. https://www.amerimmune.com/pstat-validation (accessed October 17, 2023). 533 **October 17, 2023).**<br>534 **1271** Ryberd M, Plassme
- 534 [27] Ryherd M, Plassmeyer M, Alexander C, Eugenio I, Kleschenko Y, Badger A, et al. Improved panels<br>535 for clinical immune phenotyping: Utilization of the violet laser Cytometry R Clin Cytom 535 for clinical immune phenotyping: Utilization of the violet laser. Cytometry B Clin Cytom<br>536 2018;94:671–9. https://doi.org/10.1002/cyto.b.21532. 536 2018;94:671–9. https://doi.org/10.1002/cyto.b.21532.<br>537 [28] Jumper J, Evans R, Pritzel A, Green T, Figurnov M, R
- 537 [28] Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021;596:583-9. https://doi.org/10.1038/s41586-021-538 structure prediction with AlphaFold. Nature 2021;596:583–9. https://doi.org/10.1038/s41586-021-<br>539 03819-2. 539 03819-2.<br>540 1291 Pettersen
- 540 [29] Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF CHIMERAX $\Box$ :<br>541 Structure visualization for researchers, educators, and developers. Protein Science 2021:30:70–82 541 Structure visualization for researchers, educators, and developers. Protein Science 2021;30:70–82.<br>542 https://doi.org/10.1002/pro.3943.
- <sup>542</sup>https://doi.org/10.1002/pro.3943. 543 [30] Dogan M, Kozhaya L, Placek L, Karabacak F, Yigit M, Unutmaz D. Targeting SARS $\Box$ COV  $\Box$ 2<br>544 **bunut infection through CAR** $\Box$ **T**  $\Box$ like bispecific T cell engagers incorporating ACE2. Clin &amp: Tra 544 infection through CAR $\Box T \Box$ like bispecific T cell engagers incorporating ACE2. Clin & amp; Trans Imm 2022;11:e1421. https://doi.org/10.1002/cti2.1421.
- 545 Imm 2022;11:e1421. https://doi.org/10.1002/cti2.1421.<br>546 [31] Dogan M, Karhan E, Kozhaya L, Placek L, Chen X, Yi 546 [31] Dogan M, Karhan E, Kozhaya L, Placek L, Chen X, Yigit M, et al. Engineering Human MAIT Cells<br>547 with Chimeric Antigen Receptors for Cancer Immunotherapy. The Journal of Immunology 547 with Chimeric Antigen Receptors for Cancer Immunotherapy. The Journal of Immunology<br>548 2022;209:1523–31. https://doi.org/10.4049/jimmunol.2100856. 548 2022;209:1523–31. https://doi.org/10.4049/jimmunol.2100856.<br>549 [32] VCV000328593.9 - ClinVar - NCBI n.d.
- 549 [32] VCV000328593.9 ClinVar NCBI n.d.<br>550 https://www.ncbi.nlm.nih.gov/clinvar/var 550 https://www.ncbi.nlm.nih.gov/clinvar/variation/328593/?new\_evidence=true (accessed October 1, 2023). 551 2023).<br>552 5331 Cho D.
- 552 [33] Cho D-Y, Hunter RC, Ramakrishnan VR. The Microbiome and Chronic Rhinosinusitis. Immunol<br>553 [34] Allergy Clin North Am 2020:40:251–63 https://doi.org/10.1016/i.jac.2019.12.009 553 Allergy Clin North Am 2020;40:251–63. https://doi.org/10.1016/j.iac.2019.12.009.<br>554 [34] Säemann MD, Parolini O, Böhmig GA, Kelemen P, Krieger P-M, Neumüller J, et a
- <sup>554</sup>[34] Säemann MD, Parolini O, Böhmig GA, Kelemen P, Krieger P-M, Neumüller J, et al. Bacterial 555 metabolite interference with maturation of human monocyte-derived dendritic cells. J Leukoc Biol<br>556 2002;71:238–46.
- 556 2002;71:238–46.<br>557 5351 Sogkas G. Atsche <sup>557</sup>[35] Sogkas G, Atschekzei F, Schacht V, Von Falck C, Jablonka A, Jacobs R, et al. First Association of 558 Interleukin 12 Receptor Beta 1 Deficiency with Sjögren's Syndrome. Front Immunol 2017;8:885.<br>559 https://doi.org/10.3389/fimmu.2017.00885.
- 559 https://doi.org/10.3389/fimmu.2017.00885.<br>560 [36] Uzel G, Frucht DM, Fleisher TA, Holland S 560 [36] Uzel G, Frucht DM, Fleisher TA, Holland SM. Detection of Intracellular Phosphorylated STAT-4<br>561 by Flow Cytometry. Clinical Immunology 2001;100:270–6. https://doi.org/10.1006/clim.2001.507 <sup>561</sup>by Flow Cytometry. Clinical Immunology 2001;100:270–6. https://doi.org/10.1006/clim.2001.5078.

- 562 [37] Fieschi C. A novel form of complete IL-12/IL-23 receptor 1 deficiency with cell surface-expressed<br>563 nonfunctional receptors. Blood 2004;104:2095–101. https://doi.org/10.1182/blood-2004-02-0584.
- 563 nonfunctional receptors. Blood 2004;104:2095–101. https://doi.org/10.1182/blood-2004-02-0584.<br>564 [38] Hamilos DL. Host-microbial interactions in patients with chronic rhinosinusitis. Journal of Allergy 564 [38] Hamilos DL. Host-microbial interactions in patients with chronic rhinosinusitis. Journal of Allergy<br>565 and Clinical Immunology 2013;131:1263-1264.e6. https://doi.org/10.1016/j.jaci.2013.02.020.
- 565 and Clinical Immunology 2013;131:1263-1264.e6. https://doi.org/10.1016/j.jaci.2013.02.020.<br>566 [39] Chung K-S, Choi JW, Shin J-S, Kim S-Y, Han H-S, Kim S-Y, et al. Strain-Specific Identificat 566 [39] Chung K-S, Choi JW, Shin J-S, Kim S-Y, Han H-S, Kim S-Y, et al. Strain-Specific Identification and In Vivo Immunomodulatory Activity of Heat-Killed Latilactobacillus sakei K040706. Foods 567 and In Vivo Immunomodulatory Activity of Heat-Killed Latilactobacillus sakei K040706. Foods<br>568 2021;10:3034. https://doi.org/10.3390/foods10123034.
- 568 2021;10:3034. https://doi.org/10.3390/foods10123034.<br>569 [40] Chiarella SE, Grammer LC. Immune deficiency in chro 569 [40] Chiarella SE, Grammer LC. Immune deficiency in chronic rhinosinusitis: screening and treatment.<br>570 Expert Rev Clin Immunol 2017;13:117–23. https://doi.org/10.1080/1744666X.2016.1216790.
- 570 Expert Rev Clin Immunol 2017;13:117–23. https://doi.org/10.1080/1744666X.2016.1216790.<br>571 [41] Alpan O, Loizou D, Santos I, Ness B, Plandowski J. Impact of immune work-up on outcomes a 571 [41] Alpan O, Loizou D, Santos I, Ness B, Plandowski J. Impact of immune work-up on outcomes and<br>572 the cost of care in patients with Chronic Rhinosinusitis. Allergy 2019;74:1802–5. 572 the cost of care in patients with Chronic Rhinosinusitis. Allergy 2019;74:1802–5.<br>573 https://doi.org/10.1111/all.13793.
- 573 https://doi.org/10.1111/all.13793.<br>574 [42] Quinteiro-Filho WM, Brisbin JT, 1 574 [42] Quinteiro-Filho WM, Brisbin JT, Hodgins DC, Sharif S. Lactobacillus and Lactobacillus cell-free culture supernatants modulate chicken macrophage activities. Res Vet Sci 2015;103:170–5. 575 culture supernatants modulate chicken macrophage activities. Res Vet Sci 2015;103:170–5.<br>576 https://doi.org/10.1016/j.rvsc.2015.10.005.
- 576 https://doi.org/10.1016/j.rvsc.2015.10.005.<br>577 [43] Rocha-Ramírez LM, Pérez-Solano RA, Cas 577 [43] Rocha-Ramírez LM, Pérez-Solano RA, Castañón-Alonso SL, Moreno Guerrero SS, Ramírez<br>578 Pacheco A, García Garibay M, et al. Probiotic Lactobacillus Strains Stimulate the Inflammatc 578 Pacheco A, García Garibay M, et al. Probiotic Lactobacillus Strains Stimulate the Inflammatory<br>579 Response and Activate Human Macrophages. J Immunol Res 2017;2017:4607491. 579 Response and Activate Human Macrophages. J Immunol Res 2017;2017:4607491.<br>580 https://doi.org/10.1155/2017/4607491. 580 https://doi.org/10.1155/2017/4607491.<br>581 [44] Ellis S. Lin EL Tartar D. Immunology
- 581 [44] Ellis S, Lin EJ, Tartar D. Immunology of Wound Healing. Curr Derm Rep 2018;7:350–8.<br>582 https://doi.org/10.1007/s13671-018-0234-9 582 https://doi.org/10.1007/s13671-018-0234-9.<br>583 [45] Eming SA, Krieg T, Davidson JM. Inflamm
- 583 [45] Eming SA, Krieg T, Davidson JM. Inflammation in Wound Repair: Molecular and Cellular Mechanisms. Journal of Investigative Dermatology 2007;127:514–25. 584 Mechanisms. Journal of Investigative Dermatology 2007;127:514–25.<br>585 https://doi.org/10.1038/sj.jid.5700701. 585 https://doi.org/10.1038/sj.jid.5700701.<br>586 [46] Raziyeva K, Kim Y, Zharkinbekov Z, l
- 586 [46] Raziyeva K, Kim Y, Zharkinbekov Z, Kassymbek K, Jimi S, Saparov A. Immunology of Acute and<br>587 Chronic Wound Healing. Biomolecules 2021;11:700. https://doi.org/10.3390/biom11050700.
- 587 Chronic Wound Healing. Biomolecules 2021;11:700. https://doi.org/10.3390/biom11050700.<br>588 [47] Dumitru C, Kabat AM, Maloy KJ. Metabolic Adaptations of CD4+ T Cells in Inflammatory 588 [47] Dumitru C, Kabat AM, Maloy KJ. Metabolic Adaptations of CD4+ T Cells in Inflammatory<br>589 **Disease.** Front Immunol 2018:9:540. https://doi.org/10.3389/fimmu.2018.00540.
- 589 Disease. Front Immunol 2018;9:540. https://doi.org/10.3389/fimmu.2018.00540.<br>590 [48] Linehan JL, Harrison OJ, Han S-J, Byrd AL, Vujkovic-Cvijin I, Villarino AV, et 590 [48] Linehan JL, Harrison OJ, Han S-J, Byrd AL, Vujkovic-Cvijin I, Villarino AV, et al. Non-classical<br>591 Immunity Controls Microbiota Impact on Skin Immunity and Tissue Repair. Cell 2018;172:784-591 Immunity Controls Microbiota Impact on Skin Immunity and Tissue Repair. Cell 2018;172:784-<br>592 796.e18. https://doi.org/10.1016/j.cell.2017.12.033.
- 592 796.e18. https://doi.org/10.1016/j.cell.2017.12.033.<br>593 [49] Vemuri R, Gundamaraju R, Shinde T, Perera AP, Ba 593 [49] Vemuri R, Gundamaraju R, Shinde T, Perera AP, Basheer W, Southam B, et al. Lactobacillus acidophilus DDS-1 Modulates Intestinal-Specific Microbiota, Short-Chain Fatty Acid and 594 acidophilus DDS-1 Modulates Intestinal-Specific Microbiota, Short-Chain Fatty Acid and<br>595 Immunological Profiles in Aging Mice. Nutrients 2019;11:1297. 595 Immunological Profiles in Aging Mice. Nutrients 2019;11:1297.<br>596 https://doi.org/10.3390/nu11061297. 596 https://doi.org/10.3390/nu11061297.<br>597
- 
- 598

# <sup>599</sup>**Figure legends:**

- <sup>600</sup>**Figure 1**
- <sup>601</sup>Characterizing of the patient. A) Endoscopic photograph of the patient's sinus. B) Sanger
- 602 sequencing of the *IL12Rb1* gene. C) Pedigree of the patient and her family. D) CD212
- 603 (IL12R $\beta$ 1) expression on CD4 and CD20 lymphocytes.

![](_page_24_Picture_153.jpeg)

- <sup>605</sup>**Figure 2**
- 606 Stimulation of PBMC with PMA and ionomycin. The percentages of  $CD3^+/CD4^+$  lymphocytes
- 607 that produces IL-17 (normal range  $0.2\%$ -2.2%) and IFN $\gamma$  (normal range 3-30%) were determined
- 608 by flow cytometry.

609

- <sup>610</sup>**Figure 3**
- 611 The mutation affects IL-12 signaling. PBMC stimulated with IL-12, IL-18, IL-2 and
- 612 CD3&CD28 beads. The IFN $\gamma$  production were measured in CD3<sup>+</sup>/CD4<sup>+</sup> lymphocytes. The
- 613 experiment was repeated three times. Representative plots are shown.

#### <sup>615</sup>**Figure 4**

- 616 STAT4 phosphorylation in response to IL-12 stimulation. A) representative plots. B) Results
- 617 from the patient, healthy controls and CVID patients. C) Four of the patient's children. " $+$ "

618 indicates wt allele and "-" indicates the mutation.

- <sup>620</sup>**Figure 5**
- 621 Effect of  $IL12R\beta1$  expression on IL-12 induced STAT4 phosphorylation in Jurkat cells.
- 622 Histograms overlay representing pStat4 after stimulation of wild type or engineered Jurkat cells
- 623 with wt IL12Rb2, wt IL12Rb1 or both receptors.

#### <sup>625</sup>**Figure 6**

![](_page_25_Picture_99.jpeg)

![](_page_26_Picture_1.jpeg)

![](_page_26_Picture_2.jpeg)

A B

![](_page_26_Figure_3.jpeg)

![](_page_26_Figure_4.jpeg)

![](_page_27_Picture_1.jpeg)

![](_page_27_Figure_2.jpeg)

![](_page_28_Picture_1.jpeg)

![](_page_28_Figure_2.jpeg)

![](_page_28_Figure_3.jpeg)

![](_page_29_Picture_1.jpeg)

![](_page_29_Figure_3.jpeg)

![](_page_29_Figure_4.jpeg)

![](_page_30_Picture_1.jpeg)

![](_page_30_Figure_2.jpeg)

![](_page_31_Picture_1.jpeg)

A

![](_page_31_Figure_3.jpeg)

![](_page_31_Figure_4.jpeg)

![](_page_32_Picture_1.jpeg)

![](_page_32_Figure_2.jpeg)

![](_page_33_Picture_1.jpeg)

![](_page_33_Figure_2.jpeg)

![](_page_34_Picture_1.jpeg)

![](_page_34_Figure_2.jpeg)

B **Reduction in lactobacilli induced STAT4 phosphorylation by αIL-12**

![](_page_34_Figure_4.jpeg)

![](_page_35_Picture_0.jpeg)

![](_page_35_Picture_2.jpeg)